Radiomics and gene expression profile to characterise the disease and predict outcome in patients with lung cancer

[1]  A. Chiti,et al.  Deep learning in Nuclear Medicine—focus on CNN-based approaches for PET/CT and PET/MR: where do we stand? , 2021, Clinical and Translational Imaging.

[2]  H. Bai,et al.  EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma , 2020, Journal for ImmunoTherapy of Cancer.

[3]  Riemer H. J. A. Slart,et al.  Artificial intelligence and hybrid imaging: the best match for personalized medicine in oncology , 2020, European Journal of Hybrid Imaging.

[4]  Yue-Yang Xie,et al.  GC-Derived EVs Enriched with MicroRNA-675-3p Contribute to the MAPK/PD-L1-Mediated Tumor Immune Escape by Targeting CXXC4 , 2020, Molecular therapy. Nucleic acids.

[5]  C. Zhan,et al.  Genetic and microenvironmental differences in non-smoking lung adenocarcinoma patients compared with smoking patients , 2020, Translational lung cancer research.

[6]  Lemeng Zhang,et al.  Identification of the key genes and characterizations of Tumor Immune Microenvironment in Lung Adenocarcinoma (LUAD) and Lung Squamous Cell Carcinoma (LUSC) , 2020, Journal of Cancer.

[7]  E. Neri,et al.  Imaging-Based Prediction of Molecular Therapy Targets in NSCLC by Radiogenomics and AI Approaches: A Systematic Review , 2020, Diagnostics.

[8]  M. Lai,et al.  Overexpressed gene signature of EPH receptor A/B family in cancer patients-comprehensive analyses from the public high-throughput database. , 2020, International journal of clinical and experimental pathology.

[9]  L. Cozzi,et al.  PET/CT radiomics in breast cancer: mind the step. , 2020, Methods.

[10]  Liang Liu,et al.  Neferine induces autophagy-dependent cell death in apoptosis-resistant cancers via ryanodine receptor and Ca2+-dependent mechanism , 2019, Scientific Reports.

[11]  M. Sollini,et al.  Quantitative imaging biomarkers in nuclear medicine: from SUV to image mining studies. Highlights from annals of nuclear medicine 2018 , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  Martina Sollini,et al.  Towards clinical application of image mining: a systematic review on artificial intelligence and radiomics , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  Stefano Trebeschi,et al.  Radiogenomics: bridging imaging and genomics , 2019, Abdominal Radiology.

[14]  E. D. de Vries,et al.  MAPK pathway activity plays a key role in PD‐L1 expression of lung adenocarcinoma cells , 2019, The Journal of pathology.

[15]  Gregory M. Cooper,et al.  CADD: predicting the deleteriousness of variants throughout the human genome , 2018, Nucleic Acids Res..

[16]  Franco Turini,et al.  A Survey of Methods for Explaining Black Box Models , 2018, ACM Comput. Surv..

[17]  K. Togashi,et al.  Usefulness of gradient tree boosting for predicting histological subtype and EGFR mutation status of non-small cell lung cancer on 18F FDG-PET/CT , 2019, Annals of Nuclear Medicine.

[18]  Wojciech Samek,et al.  Explainable AI: Interpreting, Explaining and Visualizing Deep Learning , 2019, Explainable AI.

[19]  Rui Li,et al.  Elevated mRNA Levels of AURKA, CDC20 and TPX2 are associated with poor prognosis of smoking related lung adenocarcinoma using bioinformatics analysis , 2018, International journal of medical sciences.

[20]  P. V. Van Schil,et al.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  Shi-bin Yang,et al.  The close association between IL‑12Rβ2 and p38MAPK, and higher expression in the early stages of NSCLC, indicates a good prognosis for survival. , 2018, Molecular medicine reports.

[22]  Elaine R. Mardis,et al.  The emerging clinical relevance of genomics in cancer medicine , 2018, Nature Reviews Clinical Oncology.

[23]  A. Moll,et al.  Non-invasive tumor genotyping using radiogenomic biomarkers, a systematic review and oncology-wide pathway analysis , 2018, Oncotarget.

[24]  L. Cozzi,et al.  Ability of FDG PET and CT radiomics features to differentiate between primary and metastatic lung lesions , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[25]  B. Sundaram,et al.  Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecula , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  L. Cozzi,et al.  Prediction of disease-free survival by the PET/CT radiomic signature in non-small cell lung cancer patients undergoing surgery , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[27]  L Cozzi,et al.  PET Radiomics in NSCLC: state of the art and a proposal for harmonization of methodology , 2017, Scientific Reports.

[28]  Ting-Yi Sung,et al.  Phosphoproteomics Reveals HMGA1, a CK2 Substrate, as a Drug-Resistant Target in Non-Small Cell Lung Cancer , 2017, Scientific Reports.

[29]  Stefan Leger,et al.  Image biomarker standardisation initiative version 1 . 4 , 2016, 1612.07003.

[30]  M Oudkerk,et al.  Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  Steffen Löck,et al.  Image biomarker standardisation initiative , 2016 .

[32]  D. Groheux,et al.  FDG PET-CT for solitary pulmonary nodule and lung cancer: Literature review. , 2016, Diagnostic and interventional imaging.

[33]  P. Lambin,et al.  Exploratory Study to Identify Radiomics Classifiers for Lung Cancer Histology , 2016, Front. Oncol..

[34]  Isabella Castiglioni,et al.  A fully automatic, threshold-based segmentation method for the estimation of the Metabolic Tumor Volume from PET images: validation on 3D printed anthropomorphic oncological lesions , 2016 .

[35]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[36]  E. Griffis,et al.  The nucleoporin ALADIN regulates Aurora A localization to ensure robust mitotic spindle formation , 2015, Molecular biology of the cell.

[37]  I. El Naqa,et al.  A radiomics model from joint FDG-PET and MRI texture features for the prediction of lung metastases in soft-tissue sarcomas of the extremities , 2015, Physics in medicine and biology.

[38]  G. Barreto,et al.  Epigenetics in lung cancer diagnosis and therapy , 2015, Cancer and Metastasis Reviews.

[39]  Eric J. W. Visser,et al.  FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[40]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[41]  Jie Sun,et al.  New tumor suppressor CXXC finger protein 4 inactivates mitogen activated protein kinase signaling , 2014, FEBS letters.

[42]  Y. Yoshioka,et al.  Ephrin receptor A10 is a promising drug target potentially useful for breast cancers including triple negative breast cancers. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[43]  S Senan,et al.  2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  P. Lambin,et al.  Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach , 2014, Nature Communications.

[45]  M. Parat,et al.  Assessment of gene expression of intracellular calcium channels, pumps and exchangers with epidermal growth factor-induced epithelial-mesenchymal transition in a breast cancer cell line , 2013, Cancer Cell International.

[46]  Maria Carla Gilardi,et al.  TOUCH-SUV: a Touchscreen-Assisted Tool for Quantitative, Reproducible, Clinically Feasible and Collaborative Diagnostic Reporting of Whole-Body PET-CT Studies , 2012 .

[47]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[48]  Yang Liu,et al.  Dishevelled‐1 and dishevelled‐3 affect cell invasion mainly through canonical and noncanonical Wnt pathway, respectively, and associate with poor prognosis in nonsmall cell lung cancer , 2010, Molecular carcinogenesis.

[49]  W. Oyen,et al.  FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[50]  D. Ribatti,et al.  IL-12 Can Target Human Lung Adenocarcinoma Cells and Normal Bronchial Epithelial Cells Surrounding Tumor Lesions , 2009, PloS one.

[51]  Hiromu Suzuki,et al.  Decreased expression of CXXC4 promotes a malignant phenotype in renal cell carcinoma by activating Wnt signaling , 2009, Oncogene.

[52]  Vladimir Vezhnevets,et al.  “GrowCut” - Interactive Multi-Label N-D Image Segmentation By Cellular Automata , 2005 .

[53]  Biao He,et al.  Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression , 2003, Oncogene.

[54]  Christian Pilarsky,et al.  WIF1, a component of the Wnt pathway, is down‐regulated in prostate, breast, lung, and bladder cancer , 2003, The Journal of pathology.